ImmuPharma Biotech

ImmuPharma Biotech is specialised in the development of new therapies based on peptides and related molecules.

Our proprietary technologies and expertise allow us to design active compounds with optimised ADMET properties. ADMET: Administration, Distribution, Metabolism, Excretion, and Toxicity.

Our therapeutic focus is primarily autoimmune/inflammatory diseases and infectious diseases.

From left to right: Margaux Fernandez, Intern (M2); Louis-Aymar Brisset, Research Assistant; Sébastien Goudreau, Chief Executive Officer, ImmuPharma Biotech; Laura Mauran-Ambrosino, Chief Scientific Officer, ImmuPharma Biotech; Marie-Cécile Srour, Research Assistant; Claire Venin, Research Scientist; Alice Brûlet, Research Assistant

Sébastien R. Goudreau, Ph.D.

Chief Executive Officer, ImmuPharma Biotech

Born in Sherbrooke, Québec, Canada, Dr Goudreau obtained his PhD in Chemistry at the Université of Montréal as a NSERC fellow before moving to Switzerland to conduct postdoctoral studies at the ETH Zürich as an FRQNT fellow. He then moved back to Canada for one year where he co-founded FindMolecule inc. and worked for the pharma industry.

In 2014 he joined ImmuPharma as research director and established the research laboratories of Ureka in Bordeaux. After the merger of ELRO with Ureka in 2019, Dr Goudreau became Chief Scientific Officer of Ureka Pharma and in 2021, he became Chief Executive Officer of ImmuPharma Biotech. Notably, Dr Goudreau and his team are credited for the discovery and development of, among others, URK 614, BioGlucagon, and BioAMB.

Laura Mauran-Ambrosino, Ph.D.

Chief Scientific Officer, ImmuPharma Biotech

Born in Montpellier, France, Dr Mauran- Ambrosino obtained her PhD in Chemistry at the Université de Bordeaux as a CIFRE fellow in co-supervision by Dr Goudreau.

She then conducted postdoctoral studies at the “Centre Hospitalier Universitaire” Pellegrin in cell biology. In 2018, she joined Ureka and established the biology department and the analytical chemistry department and in 2021, she became Chief Scientific Officer of Ureka Pharma. Dr Mauran-Ambrosino was a key contributor to the development of BioGlucagon, and BioAMB.